Bulletin of Experimental Biology and Medicine

, Volume 160, Issue 1, pp 84–87 | Cite as

Antiangiogenic Activity of Alofanib, an Allosteric Inhibitor of Fibroblast Growth Factor Receptor 2

  • D. A. Khochenkov
  • E. Sch. Solomko
  • N. M. Peretolchina
  • O. O. Ryabaya
  • E. V. Stepanova
Article
  • 80 Downloads

Alofanib is a potential allosteric inhibitor of FGFR2 used in oncology. The inhibitor blocks the extracellular part of the receptor and prevents its binding with the ligand. Alofanib suppressed proliferation of endothelial cells, their migration activity, and ability to form vessellike structures in vitro and significantly decreased the number of microvessels in Matrigel implant and in ovarian cancer (SKOV-3) xenograft in vivo. The results indicate that Alofanib can inhibit angiogenesis.

Key Words

alofanib allosteric inhibitor of FGFR2 tumor angiogenesis endothelial cells 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    E. Sh. Solomko, E. V. Stepanova, M. R. Lichinitser, and A. Yu. Baryshnikov, Ross. Bioterapevt. Zh., 6, No. 3, 3-7 (2007).Google Scholar
  2. 2.
    P. Carmeliet and R. K. Jain, Nature, 407, 249-257 (2000).CrossRefPubMedGoogle Scholar
  3. 3.
    T. Ho, C. L. Warneke, A. Hoang, et al., J. Clin. Oncol., 31, No. 6, Suppl., 386 (2013).Google Scholar
  4. 4.
    M. Korc and R. E. Friesel, Curr. Cancer Drug Targets, 9, No. 5, 639-651 (2009).PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    B. Kwabi-Addo, M. Ozen, and M. Ittmann, Endocr. Relat. Cancer, 11, No. 4, 709-724 (2004).CrossRefPubMedGoogle Scholar
  6. 6.
    V. Lindner, R. A. Majack, and M. A. Reidy, J. Clin. Invest., 85, No. 6, 2004-2008 (1990).PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    K. A. O’Connell and M. Edidin, J. Immunol., 144, No. 2, 521-525 (1990).PubMedGoogle Scholar
  8. 8.
    D. M. Ornitz, J. Xu, J. S. Colvin, et al., J. Biol. Chem., 271, No. 25, 15 292-15 297 (1996).Google Scholar
  9. 9.
    A. Passaniti, R. M. Taylor, R. Pili, et al., Lab. Invest., 67, No. 4, 519-528 (1992).PubMedGoogle Scholar
  10. 10.
    J. A. Takahashi, M. Fukumoto, K. Igarashi, et al., J. Neurosurg., 76, No. 5, 792-798 (1992).CrossRefPubMedGoogle Scholar
  11. 11.
    I. Tsimafeyeu, F. Daeyaert, W. Yin, et al., Eur. J. Cancer, 50, Suppl. 6, 155 (2014).CrossRefGoogle Scholar
  12. 12.
    I. Tsimafeyeu, E. Stepanova, E. Solomko, et al., Cancer Res., 74, No. 19, Suppl., a1737 (2014).CrossRefGoogle Scholar
  13. 13.
    I. Tsimafeyeu, N. Wynn, M. Gordiyev, and A. Khasanova, Cancer Res., 73, No. 8, Suppl., a4069 (2013).CrossRefGoogle Scholar
  14. 14.
    I. Tsimafeyeu, N. Wynn, E. Zaveleva, and E. Stepanova, Eur. Urology Suppl., 12, No. 6, 126 (2013).CrossRefGoogle Scholar
  15. 15.
    I. Tsimafeyeu, E. Zaveleva, E. Stepanova, and W. Low, Invest. New Drugs, 31, No. 6, 1436-1443 (2013).CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • D. A. Khochenkov
    • 1
  • E. Sch. Solomko
    • 1
  • N. M. Peretolchina
    • 1
  • O. O. Ryabaya
    • 1
    • 2
  • E. V. Stepanova
    • 1
  1. 1.N. N. Blokhin Russian Cancer Research CenterMoscowRussia
  2. 2.N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian FederationMoscowRussia

Personalised recommendations